KD Market research launches a new market research report on
the Albumin
Market. The study
covers a detailed in-depth analysis of the global market along with the
regional and country level analysis. The study also delivers a complete
analysis about the major & niche players of Albumin Market which
includes profiling of Grifols, S.A., Octapharma AG, China Biologic Products,
Inc., Ventria Bioscience,. Shire Plc, CSL Limited, Albumedix Ltd., Merck KGaA ,
Thermo Fisher Scientific, Baxter International Inc..
Albumin is globular protein found in blood plasma. Serum albumin is the most abundant plasma protein, constituting around 50% of human plasma protein. Albumin is obtained from plasma fractionation process where human serum albumin and bovine serum albumin is most widely used. Recombinant albumin is produced using recombinant techniques in rice plants, yeast species, and other cell lines. Albumin is used as blood volumizer and is employed in the treatment of various diseases including surgical blood loss, shock, burns, trauma, chronic liver disease, hypovolemia, hemorrhage, acute liver failure, hypoalbuminemia, and acute respiratory distress syndrome.
Albumin is globular protein found in blood plasma. Serum albumin is the most abundant plasma protein, constituting around 50% of human plasma protein. Albumin is obtained from plasma fractionation process where human serum albumin and bovine serum albumin is most widely used. Recombinant albumin is produced using recombinant techniques in rice plants, yeast species, and other cell lines. Albumin is used as blood volumizer and is employed in the treatment of various diseases including surgical blood loss, shock, burns, trauma, chronic liver disease, hypovolemia, hemorrhage, acute liver failure, hypoalbuminemia, and acute respiratory distress syndrome.
Request sample Copy@ https://www.kdmarketresearch.com/sample/3208
The global albumin market was valued at $5,381 million in
2016, and is projected to reach $10,305 million at a CAGR of 9.6% from 2017 to
2023. Increase in prevalence of rare diseases, shocks, trauma, burns, and other
fatalities is the major factor that contributes toward the growth of the
albumin market. Moreover, other factors that fuel the market growth include
increase in adoption of albumin products, growth in awareness about recombinant
albumin products, and rise in non-therapeutic application of albumin as an
excipient and drug formulating agent. However, stringent governmental
regulations and risks of side effects associated with the use of albumin-based
therapy impede the market growth. Conversely, development of cost-effective
therapeutics through large scale production and high market potential in
untapped emerging economies are expected to provide lucrative growth
opportunities for the market.
The global albumin market is segmented into product,
application, and region. Based on product, the market is divided into human
serum albumin, bovine serum albumin, and recombinant albumin. The applications
covered in the study include therapeutics, drug formulation & vaccine,
component of media, and other applications. Based on region, it is analyzed for
North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
-The study provides an in-depth analysis of the global
albumin market with current trends and future estimations from 2016 to 2023 to
elucidate the imminent investment pockets.
-Comprehensive analysis of factors that drive and restrict
the market growth is provided.
-Identification of factors instrumental in changing the
market scenario, rise in opportunities, and identification of key companies
that can influence this market on a global & regional scale are provided.
-Key players are profiled and their strategies are analyzed
thoroughly to understand the competitive outlook of the market.
Key market segments:
By Product
-Human Serum Albumin
-Bovine Serum Albumin
-Recombinant Albumin
-Bovine Serum Albumin
-Recombinant Albumin
By Application
-Therapeutics
-Drug Formulation & Vaccine
-Component of Media
-Other Applications
-Drug Formulation & Vaccine
-Component of Media
-Other Applications
By Region
-North America
-U.S.
-Canada
-Mexico
-Europe
-Germany
-France
-UK
-Italy
-Spain
-Rest of Europe
-Asia-Pacific
-Japan
-China
-India
-Australia
-South Korea
-Rest of Asia-Pacific
-LAMEA
-Brazil
-Saudi Arabia
-South Africa
-Rest of LAMEA
-U.S.
-Canada
-Mexico
-Europe
-Germany
-France
-UK
-Italy
-Spain
-Rest of Europe
-Asia-Pacific
-Japan
-China
-India
-Australia
-South Korea
-Rest of Asia-Pacific
-LAMEA
-Brazil
-Saudi Arabia
-South Africa
-Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
-Grifols, S.A.
-Octapharma AG
-China Biologic Products, Inc.
-Ventria Bioscience
-Shire Plc
-CSL Limited
-Albumedix Ltd.
-Merck KGaA
-Thermo Fisher Scientific
-Baxter International Inc.
-Octapharma AG
-China Biologic Products, Inc.
-Ventria Bioscience
-Shire Plc
-CSL Limited
-Albumedix Ltd.
-Merck KGaA
-Thermo Fisher Scientific
-Baxter International Inc.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players
are not profiled in the report. The same will be included on request)
-Biotest AG
-Medxbio Pte Ltd
-Mitsubishi Tanabe Pharma Corporation
-Kedrion Biopharma, Inc.
-HiMedia Leading BioSciences Company
-Celgene Corporation
-Medxbio Pte Ltd
-Mitsubishi Tanabe Pharma Corporation
-Kedrion Biopharma, Inc.
-HiMedia Leading BioSciences Company
-Celgene Corporation
Browse full Research Report with toc@ https://www.kdmarketresearch.com/report/3208/albumin-market-amr
Table of Content
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2. Key findings
3.2.1. Top investment pockets
3.3. Market share analysis, 2016
3.4. Market dynamics
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of rare diseases and various
life-threatening conditions
3.4.1.2. Increase in demand for albumin
3.4.1.3. Growing preferences for recombinant albumin
3.4.1.4. Rise in non-therapeutic application of albumin
3.4.1.2. Increase in demand for albumin
3.4.1.3. Growing preferences for recombinant albumin
3.4.1.4. Rise in non-therapeutic application of albumin
3.4.2. Restraints
3.4.2.1. Stringent government regulations
3.4.2.2. Risks associated with albumin
3.4.2.2. Risks associated with albumin
3.4.3. Opportunities
3.4.3.1. Opportunities in emerging economies
3.4.3.2. Development of cost effective therapeutics through large scale production
3.4.3.2. Development of cost effective therapeutics through large scale production
3.4.4. Impact analyses
3.5. Government regulations
3.6. Patent analysis (2013-2018)
3.6. Patent analysis (2013-2018)
3.6.1. Patent analysis, by year
3.6.2. Patent analysis for year 2017, by country
3.6.2. Patent analysis for year 2017, by country
CHAPTER 4: ALBUMIN MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Human serum albumin
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Bovine serum albumin
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Recombinant albumin
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5: ALBUMIN MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast (value)
5.2. Therapeutics
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.2.2. Market analysis, by country
5.3. Drug formulation & vaccines
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.3.2. Market analysis, by country
5.4. Component of media
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.4.2. Market analysis, by country
5.5. Other applications
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
CHAPTER 6: ALBUMIN MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America albumin market, by country
6.2.2. North America albumin market, by country
6.2.2.1. U.S.
6.2.2.1.1. Market size and forecast, by product
6.2.2.1.2. Market size and forecast, by application
6.2.2.1.2. Market size and forecast, by application
6.2.2.2. Canada
6.2.2.2.1. Market size and forecast, by product
6.2.2.2.2. Market size and forecast, by application
6.2.2.2.2. Market size and forecast, by application
6.2.2.3. Mexico
6.2.2.3.1. Market size and forecast, by product
6.2.2.3.2. Market size and forecast, by application
6.2.2.3.2. Market size and forecast, by application
6.2.3. North America market size and forecast, by product
6.2.4. North America market size and forecast, by application
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe market size and forecast, by country
6.3.2. Europe market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Market size and forecast, by product
6.3.2.1.2. Market size and forecast, by application
6.3.2.1.2. Market size and forecast, by application
6.3.2.2. France
6.3.2.2.1. Market size and forecast, by product
6.3.2.2.2. Market size and forecast, by application
6.3.2.2.2. Market size and forecast, by application
6.3.2.3. UK
6.3.2.3.1. Market size and forecast, by product
6.3.2.3.2. Market size and forecast, by application
6.3.2.3.2. Market size and forecast, by application
6.3.2.4. Italy
6.3.2.4.1. Market size and forecast, by product
6.3.2.4.2. Market size and forecast, by application
6.3.2.4.2. Market size and forecast, by application
6.3.2.5. Spain
6.3.2.5.1. Market size and forecast, by product
6.3.2.5.2. Market size and forecast, by application
6.3.2.5.2. Market size and forecast, by application
6.3.2.6. Rest of Europe
6.3.2.6.1. Market size and forecast, by product
6.3.2.6.2. Market size and forecast, by application
6.3.2.6.3. Europe market size and forecast, by product
6.3.2.6.4. Europe market size and forecast, by application
6.3.2.6.2. Market size and forecast, by application
6.3.2.6.3. Europe market size and forecast, by product
6.3.2.6.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Market size and forecast, by product
6.4.2.1.2. Market size and forecast, by application
6.4.2.1.2. Market size and forecast, by application
6.4.2.2. China
6.4.2.2.1. Market size and forecast, by product
6.4.2.2.2. Market size and forecast, by application
6.4.2.2.2. Market size and forecast, by application
6.4.2.3. India
6.4.2.3.1. Market size and forecast, by product
6.4.2.3.2. Market size and forecast, by application
6.4.2.3.2. Market size and forecast, by application
6.4.2.4. Australia
6.4.2.4.1. Market size and forecast, by product
6.4.2.4.2. Market size and forecast, by application
6.4.2.4.2. Market size and forecast, by application
6.4.2.5. South Korea
6.4.2.5.1. Market size and forecast, by product
6.4.2.5.2. Market size and forecast, by application
6.4.2.5.2. Market size and forecast, by application
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Market size and forecast, by product
6.4.2.6.2. Market size and forecast, by application
6.4.2.6.2. Market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by product
6.4.4. Asia-Pacific market size and forecast, by application
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Market size and forecast, by product
6.5.2.1.2. Market size and forecast, by application
6.5.2.1.2. Market size and forecast, by application
6.5.2.2. Saudi Arabia
6.5.2.2.1. Market size and forecast, by product
6.5.2.2.2. Market size and forecast, by application
6.5.2.2.2. Market size and forecast, by application
6.5.2.3. South Africa
6.5.2.3.1. Market size and forecast, by type
6.5.2.3.2. Market size and forecast, by application
6.5.2.3.2. Market size and forecast, by application
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Market size and forecast, by product
6.5.2.4.2. Market size and forecast, by application
6.5.2.4.2. Market size and forecast, by application
6.5.3. LAMEA market size and forecast, by product
6.5.4. LAMEA market size and forecast, by application
6.5.4. LAMEA market size and forecast, by application
CHAPTER 7: COMPANY PROFILES
7.1. Baxter International Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.2. China Biologic Products Holdings, Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. CSL Limited
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. Grifols S.A. (Grifols International, S.A.)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Merck KGaA
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. Novozymes A/S (Albumedix Ltd.)
7.6.1. Company overview
7.6.2. Operating business segments
7.6.3. Product portfolio
7.6.4. Business performance
7.6.2. Operating business segments
7.6.3. Product portfolio
7.6.4. Business performance
7.7. Octapharma AG
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Shire Plc. (Shire US, Inc.)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. Thermo Fisher Scientific Inc (Affymetrix, Inc.)
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. Ventria Bioscience
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating product categories
7.10.4. Product portfolio
7.10.2. Company snapshot
7.10.3. Operating product categories
7.10.4. Product portfolio
Request Exclusive Discount @ htps://www.kdmarketresearch.com/discount/3208
About Us:
KD Market Research is one of the best market research
organization that provides B2B research on the growth opportunities of the
industry which is the prime factor of the overall revenue of the organization.
We identify the pain points which our client is facing around revenue methods
and provide them with a comprehensive database which helps them to make
intelligent decisions that could ensure growth to the organization.
Our Services include market intelligence, competitive
intelligence, and customized research. These research reports help the
organizations to make quick and powerful decisions that make out highest growth
in revenue.
Contact us -
KD Market Research
150 State Street, Albany,
New York, USA 12207
Website: www.kdmarketresearch.com
Email id- sales@kdmarketresearch.com
No comments:
Post a Comment